Posting as former stockholder, I have followed this for "ages". The new numbers tell you that the good sales growth lately was almost entirely due to this largest customer. The cc suggested that transferring the business might be so difficult the customer might give up (subjective heard possibility). This filing says no: the customer is going: soon taking a business which made ALL the net profit.
Problem with an R&D led model is the time to market: it's years to FDA approval and can be years more to volume! Principal benefits from FDA clearance image-wise and sharprice-wise, but EMS provider does not.
Pro-dex should have had an agreement to keep this business. Other way to look at it is why would a company in-source?
Pdex have said they are moving towards normal EMS model, now they have to speeed up...